Uterine Preservation Via Lifestyle Transformation

Inclusion Criteria

• •Diagnosis of histologically confirmed complex atypical endometrial hyperplasia (AEH) or grade 1 endometrial cancer.
• •* Patients with a previous diagnosis of AEH or grade 1 endometrial cancer who are already being followed with conservative management with oral or LNG-IUD progestin therapy are eligible.
• •* For patients with a previous diagnosis of AEH or grade 1 endometrial cancer who have been placed on progestin prior to study entry, the duration of IUD or oral progestin use prior to trial entry should be documented.
• •Premenopausal woman with a uterus.
• •ECOG performance status of 0-2.
• •At least 18 years of age and no more than 45 years of age.
• •Undergoing uterine-sparing management (e.g. due to interest in fertility preservation, interest in uterine preservation, provider recommendation, or other reason).
• •BMI ≥ 30 kg/m\^2.
• •Prior or current receipt of progestin is allowed as above. Willingness to undergo placement of LNG-IUD at the time of study entry.
• •Ability to understand and willingness to sign an IRB approved written informed consent document.